Torka P, Akhtar OS, Reddy NM, Baysal BE, et al. Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma, results of a phase 2 study. Cancer 2022 Feb 14. doi: 10.1002/cncr.34106.
PMID: 35157306